Recognition of the mycobacterial cord factor by Mincle: relevance for granuloma formation and resistance to tuberculosis

The world's most successful intracellular bacterial pathogen, Mycobacterium tuberculosis (MTB), survives inside macrophages by blocking phagosome maturation and establishes chronic infection characterized by the formation of granulomas. Trehalose-6,6-dimycolate (TDM), the mycobacterial cord fac...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 4; p. 5
Main Author Lang, Roland
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.01.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The world's most successful intracellular bacterial pathogen, Mycobacterium tuberculosis (MTB), survives inside macrophages by blocking phagosome maturation and establishes chronic infection characterized by the formation of granulomas. Trehalose-6,6-dimycolate (TDM), the mycobacterial cord factor, is the most abundant cell wall lipid of virulent mycobacteria, is sufficient to cause granuloma formation, and has long been known to be a major virulence factor of MTB. Recently, TDM has been shown to activate the Syk-Card9 signaling pathway in macrophages through binding to the C-type lectin receptor Mincle. The Mincle-Card9 pathway is required for activation of macrophages by TDM in vitro and for granuloma formation in vivo following injection of TDM. Whether this pathway is also exploited by MTB to reprogram the macrophage into a comfortable niche has not been explored yet. Several recent studies have investigated the phenotype of Mincle-deficient mice in mycobacterial infection, yielding divergent results in terms of a role for Mincle in host resistance. Here, we review these studies, discuss possible reasons for discrepant results and highlight open questions in the role of Mincle and other C-type lectin receptors in the infection biology of MTB.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Frontiers in Inflammation, a specialty of Frontiers in Immunology.
Reviewed by: Hiromasa Inoue, Kagoshima University, Japan; Sho Yamasaki, Kyushu University, Japan
Edited by: Dov L. Boros, Wayne State University School of Medicine, USA
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2013.00005